
## **Supplementary Online Content**



**eTable 1.** Screening Examination Characteristics

eTable 2. Description of Detected Invasive Cancers

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Screening Examination Characteristics

		Digital mammography (DM)	Digital breast tomosynthesis (DBT)	Total	
N (row %)	N screens	129,369 (71.7%)	50,971 (28.3%)	180,340	
Research Center	Dartmouth/Brigham and Women's Hosp.	62,062 (48.0%)	11,848 (23.2%)	73,910 (41.0%)	
	University of Pennsylvania	2,978 (2.3%)	20,228 (39.7%)	23,206 (12.9%)	
	University of Vermont	64,329 (49.7%)	18,895 (37.1%)	83,224 (46.1%)	
Age	Mean	56.4 years	54.6 years	55.9 years	
Age categories (col %)	40-49	33,084 (25.6%)	16,826 (33.0%)	49,910 (27.7%)	
	50-64	68,231 (52.7%)	25,797 (50.6%)	94,028 (52.1%)	
	65-74	28,054 (21.7%)	8,348 (16.4%)	36,402 (20.2%)	
Breast density (col %)	Not dense	85,275 (65.9%)	30,901 (60.6%)	116,176 (64.4%)	
	Dense	44,094 (34.1%)	20,070 (39.4%)	64,164 (35.6%)	
Screening exam	First	8,734 (6.8%)	5,246 (10.3%)	13,980 (7.8%)	
	Subsequent	120,635 (93.2%)	45,725 (89.7%)	166,360 (92.2%)	

eTable 2. Description of Detected Invasive Cancers†

	Age	Total	Invasive	Poor Prognosis*	Node	Her2	Hormone	Size		Grade (row %)			
	cancers (DCIS + Invasive)	N (%)	Frogriosis	* positive	positive	receptor positive	<1 cm	1-2 cm	2+ cm	1	2	3	
DM	40-49	71	47 (66.2%)	40.4%	25.5%	17.1%	91.1%	31.8%	40.9%	27.3%	25.0%	47.7%	27.3%
	50-64	217	168 (77.4%)	35.1%	20.2%	13.0%	87.8%	45.7%	32.3%	22.0%	24.0%	50.0%	26.0%
	65-74	134	112 (83.6%)	31.3%	14.4%	19.0%	81.1%	39.3%	42.0%	18.8%	26.4%	41.5%	32.1%
	Total	422	327 (77.5%)	34.6%	19.0%	15.6%	85.9%	41.6%	36.9%	21.6%	25.0%	46.8%	28.2%
DBT	40-49	38	28 (73.7%)	25.0%	14.3%	15.4%	88.9%	53.6%	25.0%	21.4%	12.0%	56.0%	32.0%
	50-64	63	44 (69.8%)	29.6%	6.8%	15.0%	90.7%	41.9%	44.2%	14.0%	21.6%	59.5%	18.9%
	65-74	38	27 (71.0%)	22.2%	15.4%	9.1%	84.0%	59.3%	25.9%	14.8%	30.4%	65.2%	4.4%
	Total	99	139 (71.2%)	26.3%	11.2%	13.6%	88.4%	50.0%	33.7%	16.3%	21.2%	60.0%	18.8%

<sup>\*</sup> Defined as demonstrating any of the following characteristics: (1) metastases; (2) positive nodes; (3) HER2-positive and tumor size ≥ 1 cm; (4) hormone receptor-negative (both ER-and PR-) and tumor size ≥ 1 cm; (5) hormone receptor-positive (ER+ or PR+) and tumor size ≥ 2 cm. †Restricted to cancers with complete cancer characteristic data from cancer registry files.